Quantum Computing Inc vs TransMedics Group Inc — how do they compare? Quantum Computing Inc trades at $8.02 (market cap $1.86B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| QUBT | TMDX | |
|---|---|---|
Market Cap | $1.86B | $3.06B |
Sector | Technology | Technology |
52-Week High | $24.62 | $150.42 |
52-Week Low | $6.31 | $61.99 |
Enterprise Value | $927.53M | $3.46B |
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $8.22, up 2.62% today, amid bearish technical signals and challenging fundamentals. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, with negative profit margins across all metrics. However, analyst sentiment remains optimistic with a 75% buy rating and $19 consensus price target, supported by recent government funding announcements and institutional investments from BlackRock and Bank of New York Mellon.
QUBT offers speculative growth potential in quantum computing but carries significant execution risks. The stock's 131% upside to analyst targets contrasts with persistent losses and high cash burn. Investors face volatility from unproven technology commercialization while banking on long-term quantum adoption. Key catalysts include contract wins and manufacturing scale-up, but profitability remains years away.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Trailing returns across standard periods
Latest headlines on both assets
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →